GlobeNewswire Inc | Aug 19, 2021 07:00AM EDT

August 19, 2021

BALA CYNWYD, Pa., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that David Bettoun, PhD, Vice President Discovery & Non-Clinical R&D of Larimar, will be giving an oral presentation at the World Orphan Drug Congress USA 2021, taking place on August 25-27 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland. Details on the presentation, which will feature preclinical in vitro data on Larimars proprietary protein replacement therapy platform, can be found below.

Presentation Expanding Therapeutic Possibilities for Rare Diseases: UseTitle: ofCell Penetrating Peptide (CPP) Technology for Protein ReplacementDate: August 27, 2021Time: 11:35 AM ET

About Larimar TherapeuticsLarimar Therapeutics, Inc.(Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimars lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in theU.S.as a potential treatment for Friedreich's ataxia.Larimaralso plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Forward-Looking StatementsThis press release contains forward-looking statements that are based on Larimars managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimars expectations regarding its ability to resolve the clinical hold imposed by the FDA related to CTI-1601, Larimars ability to develop and commercialize CTI-1601 and other planned product candidates, Larimars planned research and development efforts, and other matters regarding Larimars business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, Larimars ability to successfully engage with the FDA and satisfactorily respond to requests from the FDA for further information and data regarding CTI-1601, the timing and outcome of Larimars planned interactions with the FDA concerning the clinical hold on CTI-1601, the success, cost and timing of Larimars product development activities, nonclinical studies and clinical trials, including CTI-1601 clinical milestones; that clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of CTI-1601 may not be predictive of the results or success of clinical trials, and assessments; the ongoing impact of the COVID-19 pandemic on Larimars future clinical trials, manufacturing, regulatory and nonclinical study timelines, ability to raise additional capital and general economic conditions; Larimars ability to optimize and scale CTI-1601s manufacturing process; Larimars ability to obtain regulatory approval for CTI-1601 and future product candidates; Larimars ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimars ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made byLarimarwith theSecurities and Exchange Commission(SEC), including but not limited to Larimars periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to theSECand available atwww.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known byLarimarand its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent views as of the date hereof.Larimarundertakes no obligation to update any forward-looking statements for any reason, except as required by law.

Investor Contact: Company Contact:Joyce Allaire Michael CelanoLifeSci Advisors Chief Financial Officerjallaire@lifesciadvisors.com mcelano@larimartx.com(212) 915-2569 (484) 414-2715